Tibulizumab (LY 3090106; 660 μg/mouse, i.p; 66 μg/mouse, s.c) effectively antagonizes the biological effects induced by human BAFF and IL-17 in the mouse[1].
In cynomolgus monkey, Tibulizumab (i.v, 0.3, 1, 5, or 20 mg/kg; or s.c, 5 mg/kg) suppresses B cell development and survival and remains functionally intact in circulation, with a prolonged half-life[1].
